Arrhythmogenic right ventricular cardiomyopathy (formerly called arrhythmogenic right ventricular dysplasia; ARVD) is emerging as a relatively common cause of sudden death in the young [1] . The disease was reported in different human populations [2] [3] [4] [5] . Although diagnostic criteria were established 8 years ago [6] , often this disease is underrecognized. Most cases are detected at autopsy because of gross findings (thinning of the right ventricular free wall, massive fibrofatty substitution of the myocardial tissue). However, because necropsy is seldom performed in cases of sudden cardiac death in those aged 35 years or older, the true frequency of the disease among cases of sudden cardiac death is probably underestimated. Autopsy cases probably represent the tip of the iceberg because, as ARVD is mostly caused by dominant mutations inherited with reduced penetrance, several subjects in the affected families may escape detection.
Isolated cases of ARVD showing a positive family history of cardiac sudden death, although still unspecified, should be regarded as potential familial cases. Conversely, a fully negative family history would suggest a case of novel mutation (possible, but improbable) or, more likely, a different disease mimicking ARVD, such as Chagas disease [7] , enterovirus infection [8] , chronic right-side myocarditis [9] , or subacute Bartonella infection [10••] . The need for an international registry of patients with ARVD has been discussed [11] .
Linkage analysis in families showing dominant inheritance of ARVD succeeded in identifying seven different ARVD loci independently involved in the determination of the disease (ARVD1, 14q23-q24; ARVD2, 1q42-q43; ARVD3, 14q12-q22; ARVD4, 2q32; ARVD5, 3p23; ARVD6, 10p12-p14; ARVD7, 10q22) [12] [13] [14] [15] [16] [17] [18] . The possibility of an even wider genetic heterogeneity than presently reported cannot be ruled out at the moment. Only one autosomal recessive form of ARVD was described so far, associated with palmoplantar keratoderma and peculiar woolly hairs. This syndrome was called Naxos syndrome, because of the concentration of cases in a Greek island [19] . The causative mutation of this disease was identified as a two-nucleotide deletion in the plakoglobin gene [20] . Recently, a genotype-phenotype correlation study, performed on 26 patients, showed that this recessive trait is fully penetrant by the time of adolescence [21•] . Plakoglobin is a key component of desmosomes and adherens junctions. It is involved in tight adhesions of many cell types, cardiomyocytes included. Interestingly, a mutation in desmoplakin, another desmosomal component, was reported to produce a similar syndrome, showing keratoderma, woolly hairs, and a dilated left ventricular cardiomyopathy, inherited as autosomal recessive and detected, as far as we know, only in Ecuador [22] . The pathogenic consequence of defects in stretch-resistant cell-to-cell adhesion complexes and in their relationships with cytoskeletal proteins may represent an interesting model for ARVDs, although right ventricular cardiomyopathy resulting from these defects seems mostly dilative in nature, as shown both in the human plakoglobin deficiency and in a recently reported mouse model, deficient in actinin-associated LIMdomain protein [23] .
Although the first ARVD locus was identified in 1994, the progress toward the identification of genes whose mutations produce ARVD was slow. Attempts to identify genes whose mutation produce ARVD1 [24] or ARVD6 [25] [26] [27] were unsuccessful until now.
On the contrary, this goal was recently achieved for ARVD2, which shows fibrofatty substitution of the myocardial tissue (although much less pronounced than in other ARVDs), but also, as a distinctive feature, polymorphic effort-induced ventricular arrhythmias. The progressive restriction of the critical chromosomal region and a positional candidate gene approach succeeded in identifying hRYR2 (cardiac ryanodine receptor) as the gene involved in ARVD2 [28••] . hRYR2, one of the largest human genes (105 exons), encodes the 565-kDa monomer of the tetrameric structure, known as cardiac ryanodine receptor, interacting with four 12-kDa FK-506 binding proteins (FKBP12.6) and playing a pivotal role in intracellular calcium homeostasis and excitation-contraction coupling. Recently, functional characterization of mutants in the predicted pore region of rabbit RYR2 was successfully attempted [29] , and the molecular basis of calcium activation of the mouse RYR2 was investigated [30] .
As soon as primers for amplification of RYR2 exons were made available to other laboratories, two additional groups detected mutations in patients diagnosed respectively with catecholaminergic ventricular tachycardia [31••] and with familial ventricular tachyarrhythmias [32••] . Presently, both of these clinical entities correspond to a single OMIM entry (OMIM 604772). It is worth noting that the Finnish group had mapped their disease gene at the same locus (1q42-q43) that was previously reported for ARVD2 [33] .
A number of missense hRYR2 mutations have been detected so far. All of them occurred in highly conserved domains of the RYR2 molecule, with no evidence of preferential clustering for a single clinical phenotype. Although different mutations might give rise to distinct clinical entities sharing in common the predisposition to develop malignant tachyarrhythmias under effort or stress, present data suggest that the three clinical phenotypes could belong to a single entity with a broad range of phenotypical variability, influenced by additional genes or by environmental factors.
Interestingly, mutations in hRYR1 (skeletal muscle ryanodine receptor) domains, corresponding to those in which hRYR2 mutations were detected, are known to produce central core disease or malignant hyperthermia.
Recently, two independent studies reported the occurrence of ARVD cases among sudden deaths during or soon after a surgery. In one report, retrospective analysis of 1700 autopsies after unexpected sudden death showed a group of 50 cases that could have been related to surgery or anesthesia or both. Among them, pathologic examination showed ARVD features in 18 cases [34•]. Another article reported two adolescents who suddenly died during a surgical procedure and subsequently were recognized as ARVD carriers at the autopsy [35•]. Unfortunately, no DNA data were considered in these studies.
In the field of clinical studies, the progress of the knowledge is slowed down by difficulty in recruitment of cases, by the long period needed for thorough familial studies, and for the follow-up of a slowly progressive disease. A large study, involving 37 families [36] , reported that among 151 patients 64% showed a mild form at the echocardiogram, 30% had a moderate form, and only 6% were affected severely. The manifestation of symptoms in the late teens or in the early adult years (mean age at diagnosis, 31 ± 13 y) supports the view that in ARVDs the myocardial disease is slowly progressive in nature, in contrast with the permanent risk of a fatal arrhythmia. The proscription of physical exercise and the treatment of symptomatic patients with antiarrhythmic drugs apparently decreased the risk of sudden death in the affected patients reported in this study.
A clinically relevant cardiomyopathy closely mimicking ARVD in humans was described in the domestic cat [37] . Moreover, ARVD was diagnosed in a female Labrador dog [38] , and autopsy findings very similar to those described in ARVD were reported in a Siberian Husky [39] . Finally, a novel mouse model of lipotoxic cardiomyopathy was produced, in which cardiac myocyte death occurs, partially by lipid-induced programmed cell death [40•].
The pathogenesis of ARVDs at the molecular and cellular level is still unclear, but the role of apoptosis [41, 42] seems to be confirmed by recent observations [43] . Morphologic patterns of apoptotic death of myocytes were reported in eight ARVD endomyocardial biopsies [44] , and a study performed on 35 patients with ARVD and 30 patients affected with idiopathic sustained ventricular tachycardia concluded that at least some cardiomyocytes and fibroblasts are subjected to apoptosis in ARVD [45] .
Unfortunately, the mechanism of activation of the apoptotic pathway in myocardial cells is still poorly understood. It was reported that ␤-adrenergic stimulation could induce in myocardiocytes dystrophin breakdown, followed by apoptosis [46] and, more recently, that apoptosis may be the myocardial response to biomechanical stress [47] . The role of protein kinase signaling pathway, with particular reference to stress-activated protein kinases, was emphasized [48] , and the release of cytochrome C and activation of cytosolic caspases after ischemia was reported [49].
It is not yet clear how mutations in genes involved in
ARVDs may be linked to the induction of apoptosis, or to a predisposition of cells to programmed death. However, several reports recently suggested that apoptosis of myocardiocytes possibly could be prevented.
It has been shown that, at physiologic concentration, 17-␤-estradiol prevents programmed cell death in myocardial cells [50•] . This would explain the well-known cardioprotective effect of estrogens, which is particularly evident in cases of ARVD because most patients are male. A series of drugs were proposed for their possible protective effect: it was reported that vesnarinone, a synthetic quinoline derivative used in the treatment of cardiac failure, suppresses tumor necrosis factor-induced activation of NF-kappaB, c-Jun kinase, and apoptosis [51••] ; that nifedipine would prevent apoptosis in cardiomyocytes [52] ; and that prolonged therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure [53] . These findings might open new perspectives in the therapeutic approach, while we still wait for the identification of primary defects in ARVDs and for the elucidation of their pathogenesis. • 2 Perzanowski C, Crespo G, Yazdanfar S: Images in cardiology: familial ventricular tachycardia with mild ventricular dysfunction: a 15 year follow up of two African American brothers with arrhythmogenic right ventricular dysplasia. Heart 2000, 84:658. This article, together with those listed as references 3-5, shows that ARVD is probably a cardiomyopathy shared by different human populations. However, data are still insufficient to assess whether the prevalence is similar in the considered human groups. Possibly, this issue might be clarified in the future by establishing an international registry (reference 11). Cardiol 2001 Cardiol , 38:1477 Cardiol -1484 . This is the first attempt to establish a genotype-phenotype correlation in this disease. Interestingly, the penetrance of the pathogenic trait was found 100%, in contrast with the reduced penetrance previously described in all the autosomal dominant forms of ARVD. 
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